Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment

Bibliographic Details
Title: Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment
Authors: Ao, Wei, Kim, Hong Im, Tommarello, Domenic, Conrads, Kelly A., Hood, Brian L., Litzi, Tracy, Abulez, Tamara, Teng, Pang-Ning, Dalgard, Clifton L., Zhang, Xijun, Wilkerson, Matthew D., Darcy, Kathleen M., Tarney, Christopher M., Phippen, Neil T., Bakkenist, Christopher J., Maxwell, G. Larry, Conrads, Thomas P., Risinger, John I., Bateman, Nicholas W.
Source: In Gynecologic Oncology October 2023 177:60-71
Database: ScienceDirect
More Details
ISSN:00908258
DOI:10.1016/j.ygyno.2023.08.004
Published in:Gynecologic Oncology
Language:English